论文部分内容阅读
采用ELlSA夹心法和~3H—TdR释放法分别对217例恶性肿瘤病人血清sIL—2R和TN0进行测定,结果发现,恶性肿瘤患者血清sIL—2R和TNF均明显高于正常对照(p<0.001),并与临床分期,肿瘤进展,以及病情的严重程度有关;伴有转移的患者血清sIL-2R和TNF升高幅度更为明显,与病情稳定或非转移患者相比有显著性差异(p<0.001)。所以,检测恶性肿瘤患者血清sIL-2R和TNF不但能了解癌症患者机体的免疫状态,且能在一定程度上对疾病的严重程度、肿瘤分期、进展、转移、疗效及预后等作出评估。
Serum levels of sIL-2R and TN0 were measured in 217 patients with malignant tumors using the ELlSA sandwich method and the ~3H-TdR release method. The results showed that serum sIL-2R and TNF were significantly higher in patients with malignant tumors than in normal controls (p<0.001). , And with the clinical stage, tumor progression, and the severity of the disease; patients with metastasis serum sIL-2R and TNF increased more significantly, and patients with stable or non-metastatic patients have significant differences (p < 0.001). Therefore, the detection of serum sIL-2R and TNF in patients with malignant tumors can not only understand the immune status of cancer patients, but also can assess the severity of the disease, tumor stage, progression, metastasis, efficacy and prognosis to a certain extent.